parsaclisib + rituximab + ifosfamide + carboplatin + etoposide

This combination consists of **parsaclisib** (a PI3Kδ inhibitor), **rituximab** (a monoclonal antibody targeting CD20 on B-cells), **ifosfamide** (an alkylating agent), **carboplatin** (a platinum-based chemotherapeutic), and **etoposide** (a topoisomerase II inhibitor). It represents an investigational, intensive **combination regimen** aimed at enhancing antitumor effects by integrating targeted immunotherapy (parsaclisib and rituximab) with cytotoxic chemotherapy (ifosfamide, carboplatin, and etoposide). Such regimens are explored primarily in aggressive lymphoid malignancies and certain solid tumors. This specific five-drug combination does not currently have a unique trade or code name and is studied mainly in research or experimental settings.